about
Treatment of gastric cancerDoublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled TrialsSunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Identification of key genes associated with gastric cancer based on DNA microarray data.Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.Efficacy of laser capture microdissection plus RT-PCR technique in analyzing gene expression levels in human gastric cancer and colon cancerPhase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility studyTreatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.The Antigastric Cancer Activity of San Leng Powder Extract Induces Apoptosis in Balb/C Bearing-SGC-7901 Mice.A role for p21-activated kinase 7 in the development of gastric cancer.Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.Chemotherapy for advanced gastric cancer: across the years for a standard of care.ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Herbal medicine Guan Chang Fu Fang enhances 5-fluorouracil cytotoxicity and affects drug-associated genes in human colorectal carcinoma cells.Gastric cancer in IndiaThe herb medicine formula "chong lou fu fang" increases the cytotoxicity of chemotherapeutic agents and down-regulates the expression of chemotherapeutic agent resistance-related genes in human gastric cancer cells in vitro.The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.Long-Term Survival of Gastric Adenocarcinoma without Therapy: Case Report.Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancerTreatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.A Comparison of Intravenous plus Intraperitoneal Chemotherapy with Intravenous Chemotherapy Alone for the Treatment of Gastric Cancer: A Meta-Analysis.Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).Double layered self-expanding metal stents for malignant esophageal obstruction, especially across the gastroesophageal junction.Decursin from Angelica gigas Nakai Inhibits B16F10 Melanoma Growth Through Induction of Apoptosis.Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancerEthanol extract of paeonia suffruticosa Andrews (PSE) induced AGS human gastric cancer cell apoptosis via fas-dependent apoptosis and MDM2-p53 pathwaysDocetaxel in the treatment of gastric cancer.Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites.Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?Divide and conquer: progress in the molecular stratification of cancerGefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study.mTOR as a therapeutic target in patients with gastric cancer.Prognostic role of SPARC expression in gastric cancer: a meta-analysis.Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study.Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer.
P2860
Q24602875-1A979B2D-0349-493F-A04A-1EFA085D68C0Q26764802-FF9111F2-EA9D-4257-851E-C19D481EFA4FQ30313895-B71B733F-C015-47CE-A020-D3CAF9A206CCQ31044596-D57ED493-EEE8-493A-A3D9-385C9B9DE723Q33317139-22AC9E33-3A74-4F6C-8476-2011AE608725Q33354817-437E7A4C-75FB-4F72-B1FA-36D267E5E71EQ33374960-1B94BE83-6B52-4043-85D3-170ECAE9182DQ33383287-B1B1E81F-F484-43D7-820E-009DC9ABDE24Q33393039-715E2C28-5A83-40A0-B523-929E0DC44626Q33405235-C0F46250-C674-4E5F-881A-0471031E8B73Q33418948-109488AD-799E-455C-8BC7-F688399D261CQ33631305-91D20BE1-8592-4C68-8C0D-7AD6ED2193EAQ33711200-B8C2FD04-8CF8-4B66-9DF5-C29BDB213DD2Q34308785-C0046B39-54B1-47A7-8B84-DC0D93A69DD8Q34450648-68B29228-541E-49FE-A02B-A587D0654DABQ34617795-BCAED263-D4CC-4F47-B7B5-EB08B1BF15BDQ34694410-B787FD64-C63D-45AB-9AF9-45280FAB48FBQ34993675-FB7FC3B9-3963-4A7D-84FD-43AE6B0CB2BAQ35073299-6707DEAB-ABF8-4C01-9219-81F127CE6989Q35109129-791A1C64-4B59-40C1-B1EB-B79FD2625D68Q35175390-7D6E5D11-9CBB-4958-9E2B-AA0EE7436DB1Q35323682-C8204990-D651-42BD-BECE-83A6D05085EAQ35615776-C7F57830-CD2A-41F4-8A1C-903D5479DFFFQ35661060-1DEB1AB4-8ACF-4F8A-9F95-09AC4AB05926Q35833346-515FFAB4-7A7A-4685-9CF7-41C50EDF0759Q35898235-C8F71D68-B9B4-44CE-97E5-987713CE0B4FQ35981433-C681E868-AC39-46A0-9DBF-3083AC1F9584Q36121251-D03AD63E-666E-4BC2-83EE-5055D6E48D1DQ36123073-5931761B-C2AB-467B-A19E-943DE90F5FF2Q36224775-7371791F-08E8-4030-8717-573F838C37BBQ36507446-3FF5CA17-617D-457B-A763-73C7B13BC1C7Q36616503-0CEC4A14-B4C1-41AD-863B-5A279791F3D1Q36628679-8F2834EA-CBBB-4606-A0D3-26FA27BD7BEDQ36964966-44E05840-AE4B-42F7-BAE7-2BDBBDFEB4DAQ37314999-8249C148-0745-4755-9A85-358EF97E382BQ37522211-C5EE2E13-C1BA-4382-9816-F1A9E6030315Q37928535-B719EDEC-BCA5-467F-95D1-862812B8FC47Q38268097-1E50743B-45E7-4894-81A3-6B71482F4D57Q38391749-10BA9AB9-C61B-43CD-B7F3-529B9EE4712FQ38695467-D9C920B7-46B5-4915-8088-D8D16044FE02
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Evolving chemotherapy for advanced gastric cancer.
@ast
Evolving chemotherapy for advanced gastric cancer.
@en
type
label
Evolving chemotherapy for advanced gastric cancer.
@ast
Evolving chemotherapy for advanced gastric cancer.
@en
prefLabel
Evolving chemotherapy for advanced gastric cancer.
@ast
Evolving chemotherapy for advanced gastric cancer.
@en
P1433
P1476
Evolving chemotherapy for advanced gastric cancer.
@en
P2093
Jaffer A Ajani
P356
10.1634/THEONCOLOGIST.10-90003-49
P478
10 Suppl 3
P577
2005-01-01T00:00:00Z